NOT FOR DISTRIBUTION
Header cover image

Hayat Pharmaceutical Industries

Market Cap

د.أ37.1m

Last Updated

2021/09/17 11:32 UTC

Data Sources

Company Financials

Executive Summary

Hayat Pharmaceutical Industries Co. PLC, together with its subsidiary, provides human and veterinary medicines in Jordan. More Details


Snowflake Analysis

Excellent balance sheet with proven track record.

Share Price & News

How has Hayat Pharmaceutical Industries's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HPIC is not significantly more volatile than the rest of JO stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: HPIC's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

0.5%

HPIC

-1.2%

JO Pharmaceuticals

-0.4%

JO Market


1 Year Return

85.7%

HPIC

-5.0%

JO Pharmaceuticals

36.5%

JO Market

Return vs Industry: HPIC exceeded the JO Pharmaceuticals industry which returned -5% over the past year.

Return vs Market: HPIC exceeded the JO Market which returned 36.5% over the past year.


Shareholder returns

HPICIndustryMarket
7 Day0.5%-1.2%-0.4%
30 Day0%-0.5%3.2%
90 Day6.3%-6.9%-6.2%
1 Year99.5%85.7%-3.7%-5.0%40.7%36.5%
3 Year123.4%85.7%29.9%23.5%11.0%0.5%
5 Year192.8%116.7%36.2%25.8%17.5%-2.9%

Long-Term Price Volatility Vs. Market

How volatile is Hayat Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hayat Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?

9.94x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: HPIC (JOD3.9) is trading above our estimate of fair value (JOD1.38)

Significantly Below Fair Value: HPIC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HPIC is good value based on its PE Ratio (9.9x) compared to the Asian Pharmaceuticals industry average (24.7x).

PE vs Market: HPIC is good value based on its PE Ratio (9.9x) compared to the JO market (13.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HPIC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HPIC is good value based on its PB Ratio (1.5x) compared to the XA Pharmaceuticals industry average (2.4x).


Future Growth

How is Hayat Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hayat Pharmaceutical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Hayat Pharmaceutical Industries performed over the past 5 years?

10.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HPIC has high quality earnings.

Growing Profit Margin: HPIC's current net profit margins (22.2%) are higher than last year (21.4%).


Past Earnings Growth Analysis

Earnings Trend: HPIC's earnings have grown by 10.5% per year over the past 5 years.

Accelerating Growth: HPIC's earnings growth over the past year (12.9%) exceeds its 5-year average (10.5% per year).

Earnings vs Industry: HPIC earnings growth over the past year (12.9%) underperformed the Pharmaceuticals industry 18.3%.


Return on Equity

High ROE: HPIC's Return on Equity (14.6%) is considered low.


Financial Health

How is Hayat Pharmaceutical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: HPIC's short term assets (JOD16.9M) exceed its short term liabilities (JOD3.7M).

Long Term Liabilities: HPIC's short term assets (JOD16.9M) exceed its long term liabilities (JOD898.1K).


Debt to Equity History and Analysis

Debt Level: HPIC's debt to equity ratio (8.5%) is considered satisfactory.

Reducing Debt: HPIC's debt to equity ratio has increased from 0.6% to 8.5% over the past 5 years.

Debt Coverage: HPIC's debt is well covered by operating cash flow (112.3%).

Interest Coverage: HPIC's interest payments on its debt are well covered by EBIT (43.3x coverage).


Balance Sheet


Dividend

What is Hayat Pharmaceutical Industries's current dividend yield, its reliability and sustainability?

2.56%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: HPIC's dividend (2.56%) isn’t notable compared to the bottom 25% of dividend payers in the JO market (3.5%).

High Dividend: HPIC's dividend (2.56%) is low compared to the top 25% of dividend payers in the JO market (6.7%).


Stability and Growth of Payments

Stable Dividend: HPIC is not paying a notable dividend for the JO market, therefore no need to check if payments are stable.

Growing Dividend: HPIC is not paying a notable dividend for the JO market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: HPIC is not paying a notable dividend for the JO market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HPIC's dividend in 3 years as they are not forecast to pay a notable one for the JO market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

د.أ150k

CEO Compensation


CEO

Maher Mohammed Al Kurdi (43 yo)

no data

Tenure

د.أ149,900

Compensation

Dr. Maher Mohammed Ali Al Kurdi is Founder of Hayat Pharmaceutical Industries Co. PLC and serves its Chairman, General Manager and Executive Director.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hayat Pharmaceutical Industries Co. PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hayat Pharmaceutical Industries Co. PLC
  • Ticker: HPIC
  • Exchange: ASE
  • Founded: 1994
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: د.أ37.050m
  • Shares outstanding: 9.50m
  • Website: https://www.hayatpharma.com

Number of Employees


Location

  • Hayat Pharmaceutical Industries Co. PLC
  • PO Box 1564
  • Amman
  • 11118
  • Jordan

Listings


Biography

Hayat Pharmaceutical Industries Co. PLC, together with its subsidiary, provides human and veterinary medicines in Jordan. The company offers products in various categories, such as anti-vertigo medication,...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/17 11:32
End of Day Share Price2021/09/14 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.